Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA OKs Valeant's New Acne Treatment - Happi
Company News

FDA OKs Valeant’s New Acne Treatment

Onexton Gel expected to launch in early 2015.

Valeant Pharmaceuticals has received approval from the Food and Drug Administration (FDA) for Onexton Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75%, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older.

Onexton Gel has a favorable cutaneous tolerability profile and contains no surfactants, alcohol or preservatives, according to Valeant, which will launch the treatment in early 2015.

Onexton is the fourth product to be approved in our medical dermatology business in the past twelve months, three of which were conceived and developed entirely by Valeant's internal R&D team, according to the company.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters